FAQ

Frequently Asked Questions 
Q1: Isn’t the ‘dark genome’ just biological noise?
Non-expressing genomic regions were never selected for function, but they still encode physicochemically valid sequence space. We treat this space as a design substrate, not a discovery problem. Our lab-validated PoCs across malaria, leishmania, antimicrobial peptides, cancer, and Alzheimer’s demonstrate that function can be engineered reliably from this space.
Q2: Why should we believe dark matter of genome can produce real biological function?
We are not extrapolating from theory. We have experimentally demonstrated measurable biochemical and cellular activity across multiple disease classes. It is a repetitive delivery experience That tells us this is a generalizable design problem, not a one-off scientific curiosity.
Q3: Isn’t this just another AI-for-biology company?
No—we don’t predict known biology; we engineer new biology. AI assists our workflow, but every design is constrained by biophysics and validated experimentally. The platform creates first-discovery molecules from non-expressing genomic space, which is fundamentally different from optimizing known proteins.
Q4: Where does quantum computation actually fit into dark genome–based drug or enzyme design?
Quantum computation strengthens the physics layer of our design engine—it does not replace classical computation or experimentation. Dark genome–derived molecules often occupy non-natural, high-complexity sequence space, where classical approximations of folding, electronic interactions, and reaction energetics begin to break down. We use quantum computation selectively to improve energy landscape modeling, electronic structure estimation, and catalytic mechanism analysis for a small but critical subset of candidates. This enables more accurate prioritization before experimental validation, reducing false positives and unnecessary wet-lab cycles.
Q5: Is quantum computation essential to the platform today, or is this speculative?
It is not required for today’s PoCs, but it is essential for long-term differentiation. Our current proofs of concept are achieved using a hybrid classical compute–experimental loop. Quantum computation is introduced where classical methods show diminishing returns, particularly for enzyme catalysis, transition-state modeling, and complex conformational spaces. We treat quantum as a precision tool, integrated in a hybrid workflow. As quantum hardware matures, this layer becomes a competitive advantage, not a dependency—allowing us to design molecules classical approaches cannot reliably evaluate.
Q6: Couldn’t a large, well-funded AI lab replicate this?
Access to data isn’t the moat—execution is. Public genomes are available to everyone. What’s hard is converting dark matter of DNA sequence logic into testable molecules, killing failures early, and learning experimentally at scale. That know-how is embedded in our past accomplishments, workflows, datasets, and validation cycles—not in raw data or generic models.
Q7: PoCs are cheap. How strong is your proof, really?
We intentionally validated across unrelated biological domains to avoid overfitting. The consistent structure–function relationships we observe demonstrate that the platform logic holds, not just individual hits. Some of the work has been published here, here, and here.
Q8: Why work across malaria, cancer, and Alzheimer’s? That looks unfocused.
These were validation sandboxes, not commercial bets. Early breadth was intentional to test generality. Now that the platform is proven, commercial focus is narrowing to areas with clear licensing and partnership pathways.
Q9: Alzheimer’s is a graveyard. Why touch it at all?
To stress-test the platform, not to build a clinical program. Our Alzheimer’s work is preclinical and mechanistic. The goal was to demonstrate that dark-genome-derived designs can function in complex biology. Commercialization occurs well upstream via licensing.
Q10: Are these molecules actually patentable if they come from natural genomes?
Yes—IP is on engineered constructs and function, not raw sequence. We file IP on engineered molecules, structures, performance, and use cases. These are first-discovery assets with no prior art, consistent with established biotech patent precedent.
Q11: Isn’t this just a services company with fancy language?
No—services sell time; we build assets. Sponsored discovery funds platform development efficiently, but long-term value comes from IP ownership, licensing, and royalties. The platform compounds; services do not.
Q12: Biology is expensive. How is this capital-efficient?
We fail early, cheaply, and informatively. Compute narrows the search space. Experiments validate quickly. Learning compounds. This dramatically reduces late-stage attrition—the most expensive failure mode in biotech.
Q13: Doesn’t wet-lab work limit scalability?
We scale by reusing validated pipelines, not reinventing experiments for every program.
Q14: What if one disease area fails?
The platform is not a single bet. Design logic and validation workflows are reusable across targets and markets. Underperformance in one area does not impair the platform.
Q15: Why is now the right time to invest?
Because the tools finally exist. Only recently have computation, experimental throughput, and capital discipline converged to make dark genome engineering viable and commercial.